The report provides a detailed analysis essential for establishing a Tacrine production plant. It encompasses all critical aspects necessary for Tacrine production, including the cost of Tacrine production, Tacrine plant cost, Tacrine production costs, and the overall Tacrine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Tacrine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Tacrine is an organic compound that works as a reversible acetylcholinesterase inhibitor, boosting acetylcholine neurotransmitter levels in the brain. It is used in the symptomatic treatment of mild to moderate Alzheimer's disease (AD). It shows improvements in cognition, behaviour, and daily functioning in clinical trials, though efficacy varied, and it required frequent liver function monitoring.
It is used as a respiratory and circulatory stimulant, an analeptic for counteracting central nervous system depression, and an antidote for anticholinesterase poisoning or reversal of non-depolarising neuromuscular blockers. Its derivatives are utilised in Parkinson's disease symptom management, neuroprotection in stroke or traumatic brain injury, and anti-inflammatory effects in neurodegenerative disorders.
The market for Tacrine is driven by growing cases of Alzheimer's disease and dementia in ageing populations. The increased healthcare investments, regulatory reforms, and rising demand for cholinesterase inhibitors fuel its market. Also, research and development activities focused on multitarget-directed tacrine derivatives and hybrids expands its applications.
The shifts toward sustainable bio-based API production to lower costs and alignment with green production standards boost its market. Its safety profile, including hepatotoxicity risks that require frequent liver monitoring, impacts industrial Tacrine procurement. The availability of superior alternatives like donepezil and rivastigmine, along with regional trade dynamics, price fluctuations, etc., affects its sourcing strategies.
Raw Material for Tacrine Production
According to the Tacrine production plant project report, the key raw materials used in the production of Tacrine include Cyclohexanone, 2-Aminobenzonitrile, and Anhydrous zinc chloride.
Production Process of Tacrine
The extensive Tacrine production cost report consists of the following major industrial production process:
- From Friedländer-style cyclocondensation reaction: The synthesis of Tacrine involves a Friedländer-style cyclocondensation reaction. The process starts by mixing Cyclohexanone with 2-aminobenzonitrile and anhydrous zinc chloride. The mixture is heated to reflux temperature and stirred for three hours. After cooling, the mixture is filtered, and the filter cake is rinsed with hexane, dispersed in water, and stirred. Sodium hydroxide solution is added to reach a basic pH, followed by filtration. The filter cake is then refluxed in ethanol, cooled, and the filtrate is rotary evaporated to precipitate the product. The precipitate is recrystallised in hot ethanol, filtered, and dried under a fume hood to yield Tacrine as the final product.
Tacrine has the molecular formula of C13H14N2 with a molecular weight of 198.27 g/mol. It is a white to off-white crystalline powder with a melting point of 183 degree Celsius. It shows moderate water solubility with a logP value of around 2.6-3.0, making it lipophilic, which is useful for CNS penetration. It is a tricyclic aminoacridine and reversibly stops acetylcholinesterase by binding the active site. It has 2 hydrogen bond acceptors, 1 donor, a polar surface area of 38.91 Ų, zero rotatable bonds, and goes through P450-mediated metabolism with oxygen insertion. All these physical and chemical properties make it useful as a reversible acetylcholinesterase inhibitor.